TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05451784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1+ TILs (NUMARZU-001) product infusion
Description: The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute.~Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following:~* Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion.~* Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist.~Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction).
Study: NCT05094765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal Microbiota Transplantation
Study: NCT06451835

Intervention type: DEVICE
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
Study: NCT05919472

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (pre-treatment)
Description: Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 1-56

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 vaccine
Description: Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MenACWY vaccine
Description: MenACWY vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY vaccine
Description: MenACWY vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY vaccine
Description: MenACWY vaccination given on day 28 to all participants

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (simultaneous treatment)
Description: Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 28-56

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Typhim Vi vaccine
Description: Typhim Vi vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi vaccine
Description: Typhim Vi vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi vaccine
Description: Typhim Vi vaccination given on day 28 to all participants
Study: NCT04071548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT Exercise
Description: HIIT exercise bike protocol~* 3 minute warm up~* Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age~* 10x60 second Recovery period~* 5 minute cool-down
Study: NCT05514587

Intervention type: BEHAVIORAL
Intervention: Meaning of Life Questionnaire (MLQ)
Description: Completion of questionnaires at crisis centre entry and 3 months later.

Intervention type: BEHAVIORAL
Intervention: Meaning of Life Questionnaire (MLQ)
Description: Completion of questionnaires at crisis centre entry and 3 months later.

Intervention type: BEHAVIORAL
Intervention: Meaning of Life Questionnaire (MLQ)
Description: Completion of questionnaires at crisis centre entry and 3 months later.
Study: NCT04871061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block
Description: Pericapsular Nerve Group Block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional opioid analgesia (Fentanyl)
Description: standardised intravenous opioid
Study: NCT04743583

Intervention type: DEVICE
Intervention: Endosonography B-mode examination
Description: Endobronchial ultrasound (EBUS) or Endoscopic with bronchoscope (EUS-B) B-mode examination and sampling, when indicated, of lymphadenopathy
Study: NCT05269706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 200mg
Description: Cannabidiol 200mg (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 200mg
Description: Cannabidiol 200mg (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex 400mg (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex 400mg (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 400mg
Description: Cannabidiol 400mg (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 400mg
Description: Cannabidiol 400mg (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo (Twice Daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo (Twice Daily)
Study: NCT04990323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Description: Single UM171-Expanded CB transplant (CD34+: 2.5-50x10\^5/kg, CD3+\>1x10\^6/kg)
Study: NCT05123664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsule
Description: 1 cap daily at same time of the day with or without food for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsule
Description: 1 cap daily at same time of the day with or without food for 4 weeks
Study: NCT05923242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Intervention Authoring Software (CIAS)
Description: CIAS is a web based intervention. The CIAS tool walks the participant through a Motivational Interviewing process whereby they think through the reasons for and against completing screening. CIAS makes use of an automated avatar (Emmi) who is programed to ask them questions and lead them through several topic areas related to screening. The CIAS pathways include options for participants to request a link of resources after they complete each session and for patients to request a list of the cancer treatments listed in their study records in order to confirm their understanding of their cancer history.
Study: NCT05853549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical surface monitoring system
Description: An optical surface monitoring system (OSMS) could achieve continuous monitoring of patient position through a nonradiographic and noninvasive technology, which has been widely applied to many sites of radiation therapy, including breast, intracranial, head and neck, abdomen, and extremities
Study: NCT06364501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH801
Description: KH801 is an injection solution
Study: NCT05315700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-114
Description: ORIC-114 oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-114
Description: ORIC-114 oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: 21 days for up to 4 cycles
Study: NCT06420492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRS201
Description: Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug for four weeks.
Study: NCT05091736

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, blood glucose monitor for personal use
Description: measurement of the blood glucose concentration using the blood glucose monitor for personal use (BG-709b)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, laboratory reference device
Description: measurement of the blood glucose concentration using a laboratory reference device
Study: NCT05407974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleurectomy
Description: All patients will undergo resection of apical blebs with simultaneous pleurectomy or pleural abrasion.~Chest tube will be inserted in the pleural cavity and maybe connected on low-grade suction for first 24 h according to type of pneumothorax \& surgeons' preference, after which the suction is disconnected.~Post Operatively both groups will be compared regarding the postoperative drainage amount, persistence of air leak (chest tube removal time), length of hospital stay, mortality and risk of recurrence.~Follow up Chest x-ray will be done immediate postoperatively, then each patient will be followed up after 6 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleurectomy
Description: All patients will undergo resection of apical blebs with simultaneous pleurectomy or pleural abrasion.~Chest tube will be inserted in the pleural cavity and maybe connected on low-grade suction for first 24 h according to type of pneumothorax \& surgeons' preference, after which the suction is disconnected.~Post Operatively both groups will be compared regarding the postoperative drainage amount, persistence of air leak (chest tube removal time), length of hospital stay, mortality and risk of recurrence.~Follow up Chest x-ray will be done immediate postoperatively, then each patient will be followed up after 6 months.
Study: NCT05245916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI397
Description: IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI397
Description: IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI397
Description: IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI397+Sintilimab
Description: IBI397 in combination with sintilimab： Subjects will receive IBI397 combination therapy with sintilimab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI397+Rituximab
Description: IBI397 in combination with rituximab： Subjects will receive IBI397 combination therapy with rituximab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
Study: NCT05845905

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by the inflation of an automated cuff to the pressure rising by 20 mmHg from baseline systolic pressure. RIC will be conducted twice daily for 7 days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham-RIC is performed in the same way as the treatment group except that the blood pressure cuff is inflated to 60 mmHg, which produces mild pressure sensations but has no blocking impact on blood flow.
Study: NCT06463392

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No intervention is scheduled for this observational study.

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No intervention is scheduled for this observational study.
Study: NCT06524492

Intervention type: DEVICE
Intervention: FlowSense
Description: This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of functional implanted shunts and off-shunt locations will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
Study: NCT04530058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg twice a day, administered orally or via gastric tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo twice a day, administered orally or via gastric tube.
Study: NCT05768763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-enhanced reach activities
Description: We will conduct a series of community engagement activities designed to reach persons at risk for HIV, undiagnosed with HIV or diagnosed, or hypertension, and fallen out of care, working closely with community health workers, integrated in the community health system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered care delivery
Description: Structured approach to provide patient-centered biomedical options for HIV prevention (dynamic choice prevention). Tailored services for HIV treatment support using structured life stage evaluation and assessment plan (LEAP) for youth, pregnant women, and persons with or at risk of HIV viral non-suppression, that includes counselling for heavy alcohol users. Structured approach to offer telehealth for severe hypertension follow up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data system enhancement to improve reach and person-centered delivery
Description: Both community-enhanced reach and person-centered delivery will be strengthened through a customized in-country Ministry of Health-compatible community health worker smartphone app and two-way data system linking community health workers and clinical records.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care in Uganda and Kenya
Study: NCT05454969

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-4-ALL Initiative
Description: We can successfully implement a patient app that will be used by families to 1) increase throughput for all patients, including minoritized, low-income, and low health literacy patients, and 2) reduce administrative burdens on providers.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients will receive standard of care.
Study: NCT05801939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be given as an IV infusion once every 3 weeks, starting roughly 10 weeks (day 70 +/- 4 days) post-CAR T cell infusion, with subjects planned to receive 8 cycles initially. Subjects receive a single step-up dose of 3.6 mg of cevostamab on cycle 1, day 1 (C1D1), followed by the recommended target dose (160 mg, 132mg, or 90 mg based on results of safety run-in data and safety review) on C1D8. Myeloma responses are assessed every cycle, and a repeat bone marrow aspirate and biopsy (BMbx) is performed at the start of cycle 8. If participants are not in an MRD-negative CR at this timepoint (or if the BM bx is inevaluable/indeterminate for CR or MRD testing), they continue with another 8 cycles (C9-16) of cevostamab. If they are in MRD-negative CR at start of C8, they stop therapy after receiving this cycle and are observed.
Study: NCT06499233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole
Description: Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole
Description: Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).
Study: NCT06138743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-DM1 for Injection
Description: single or multiple doses of ARO-DM1 by intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calculated volume to match active treatment by IV infusion
Study: NCT05785585

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Description: Treatment with Methylcobalamin during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cyanocobalamin group
Description: Treatment with Cyanocobalamin during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Treatment with microcrystalline cellulose during 12 weeks
Study: NCT06375746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized video
Description: After enrollment and assignment to the intervention group, patients will receive a link to a personalized video describing the different induction methods by a text message.
Study: NCT05927376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: All foods, meal plans and instructions provided.
Study: NCT05784324

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06560216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apigenin
Description: 0.2 mM in freezing medium
Study: NCT06192927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TenoMiR
Description: Single intralesional injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Single subcutaneous injection
Study: NCT06410001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Cord Stimulation (eSCS)
Description: The spinal cord stimulator system (Abbott Eterna system implantable pulse generator (IPG), charger, and TriCentrus lead) will be used for this study which is manufactured by Abbott Laboratories. The The stimulators will be surgically inserted above the dura in the spinal canal and administer an electrical signal from the neurostimulator to specific sections of the spinal cord underlying the electrodes. The duration of implantation will be 10 years (the longevity of the device battery). The device will not be removed unless it causes complications such as malfunction, illness, or other harm.~The device can also be removed electively for any reason.
Study: NCT05500274

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Testimonial videos will be played including those that describe the testing experience and their motivations for testing. This approach combines self-affirmation with misinformation correction to take advantage of the ability to promote adaptive COVID-19 prevention behaviors. The self-affirmation activity will always precede the presentation of the testimonial videos as leading with misinformation correction can be construed by some as a threat to one's self-adequacy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motivational
Description: This is a Type I network intervention that includes specific training on mobilization of network members. Training occurs in a group-based setting of 8-10 enrolled participants facilitated by a community facilitator and Motivational Interviewing trained interventionist. At 30 days, a 15-20-minute phone booster communication session reinforces the intervention content